{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:36:28Z","timestamp":1790289388149,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":113,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002202","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:33:39Z","timestamp":1069385619000},"source":"Crossref","is-referenced-by-count":27,"title":["Hydroxyurea for sickle cell disease"],"prefix":"10.1002","author":[{"given":"Ashley P","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally C","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebayo","family":"Olujohungbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,4,23]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD002202-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","article-title":"Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial","volume":"88","author":"Ferster","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB2|cit2","doi-asserted-by":"crossref","unstructured":"Armstrong FD Steinberg MH Ballas SK Ataga KI Waclawiw MA Kutlar A Development outcomes of offspring of adults treated with hydroxyurea in the multicenter study of hydroxyurea [abstract] Blood 2009 Abstract no: 1543","DOI":"10.1182\/blood.V114.22.1543.1543"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202-BIB3|cit3","first-page":"642a","article-title":"Narcotic analgesia use among adult patients with sickle cell anemia [abstract]","volume":"86","author":"Ballas","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB4|cit4","series-title":"Proceedings of the National Sickle Cell Disease Program 21st Annual Meeting; 1996 March","first-page":"63","article-title":"Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia [abstract]","author":"Ballas","year":"1996"},{"key":"10.1002\/14651858.CD002202-BIB5|cit5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1477-7525-4-59","article-title":"Hydroxyurea and sickle cell anemia: effect on quality of life","volume":"4","author":"Ballas","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"issue":"8","key":"10.1002\/14651858.CD002202-BIB6|cit6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ajh.21750","article-title":"Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: Effect of sex,age, and geographical location","volume":"85","author":"Ballas","year":"2010","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202-BIB7|cit7","doi-asserted-by":"crossref","unstructured":"Ballas SK Bauserman RL McCarthy WF Waclawiw MA Barton BA Impact of hydroxyurea on employment among patients with sickle cell anemia [abstract] Blood 2009 Abstract no: 2485","DOI":"10.1182\/blood.V114.22.2485.2485"},{"issue":"2","key":"10.1002\/14651858.CD002202-BIB8|cit8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2141.1999.01339.x","article-title":"Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea","volume":"105","author":"Ballas","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202-BIB9|cit9","first-page":"140a","article-title":"In vivo RBC survival and ferrokinetic data in patients with sickle cell anemia before and after treatment with hydroxyurea [abstract]","volume":"86","author":"Ballas","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB10|cit10","doi-asserted-by":"crossref","unstructured":"Ballas SK McCarthy WF Bauseman RI Castro OL Swerdlow PS Smith W Patterns of analgesic utilization in the multicenter study of hydroxyurea (MSH) [abstract] Blood 2009 Abstract no: 2577","DOI":"10.1182\/blood.V114.22.2577.2577"},{"key":"10.1002\/14651858.CD002202-BIB11|cit11","doi-asserted-by":"crossref","unstructured":"Ballas SK McCarthy WF Bauserman RL Castro OL Waclawiw MA Barton BA Sickle cell genetic markers: geographic distribution and relation to pain outcomes in multicenter study of hydroxyurea in sickle cell anemia [abstract] Blood 2009 Abstract no: 2582","DOI":"10.1182\/blood.V114.22.2582.2582"},{"issue":"22","key":"10.1002\/14651858.CD002202-BIB12|cit12","doi-asserted-by":"crossref","first-page":"Abstract no: 15","DOI":"10.1182\/blood.V114.22.1513.1513","article-title":"Definition of the responder to hydroxyurea therapy: revisited [abstract]","volume":"114","author":"Ballas","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB13|cit13","series-title":"4th Annual Sickle Cell Disease Research and Educational Symposium & Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting; 2010 Feb 14-19; Hollywood, Florida","first-page":"Abstract no: 03","article-title":"Early detection of responders to hydroxyurea therapy [abstract]","author":"Ballas","year":"2010"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD002202-BIB14|cit14","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.1016\/0197-2456(96)84580-6","article-title":"Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in Sickle Cell Anemia (MSH). The MSH Investigators [abstract]","volume":"17","author":"Barton","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202-BIB15|cit15","first-page":"209","article-title":"Vital status determination of patients' lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients' follow-up study [abstract]","volume":"2","author":"Brandon","year":"2004","journal-title":"Clinical Trials"},{"key":"10.1002\/14651858.CD002202-BIB19|cit16","first-page":"326","article-title":"Effects of hydroxyurea therapy in patients with sickle cell anemia [abstract]","volume":"26","author":"Charache","year":"1996","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002202-BIB20|cit17","first-page":"62","article-title":"Experimental therapy of sickle cell disease. Use of hydroxyurea","volume":"16","author":"Charache","year":"1994","journal-title":"American Journal of Pediatric Hematology\/Oncology"},{"issue":"3 Suppl 3","key":"10.1002\/14651858.CD002202-BIB21|cit18","first-page":"15","article-title":"Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults [review]","volume":"34","author":"Charache","year":"1997","journal-title":"Seminars in Hematology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002202-BIB22|cit19","first-page":"356a","article-title":"Preventing Pain in Sickle Cell Anemia (HB SS): Baseline Data from Patients in a Hydroxyurea Trial [abstract]","volume":"82","author":"Charache","year":"1993","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD002202-BIB16|cit20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00005792-199611000-00002","article-title":"Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \"switching\" agent","volume":"75","author":"Charache","year":"1996","journal-title":"Medicine"},{"issue":"20","key":"10.1002\/14651858.CD002202-BIB17|cit21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002202-BIB18|cit22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0197-2456(95)00098-4","article-title":"Design of the multicenter study of hydroxyurea in sickle cell anemia","volume":"16","author":"Charache","year":"1995","journal-title":"Controlled Clinical Trials"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202-BIB23|cit23","first-page":"141a","article-title":"Effect of hydroxyurea (HU) administration on the body weight, body composition and exercise performance of patients with sickle cell anemia [abstract]","volume":"86","author":"Hackney","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD002202-BIB24|cit24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1042\/cs0920481","article-title":"Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia","volume":"92","author":"Hackney","year":"1997","journal-title":"Clinical Science"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002202-BIB25|cit25","doi-asserted-by":"publisher","first-page":"92S","DOI":"10.1016\/0197-2456(96)84623-X","article-title":"Dose titration in the Multicentre Study of Hydroxyurea in Sickle Cell Anemia (MSH) [abstract]","volume":"17","author":"Handy","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202-BIB26|cit26","series-title":"Proceedings of the National Sickle Cell Disease Program 18th Annual Meeting; 1993 May","first-page":"117a","article-title":"The composition and etiology of weight gain in sickle cell patients receiving hydroxyurea (HU): An ancillary study to the multicentre study of hydroxyurea (MSH) [abstract]","author":"Heizer","year":"1993"},{"key":"10.1002\/14651858.CD002202-BIB27|cit27","series-title":"Proceedings of the National Sickle Cell Disease Program 25th Annual Meeting; 2001 April","first-page":"Abst #126","article-title":"Effect of hydroxyurea on hematologic and biochemical laboratory values in sickle cell disease: The MSH at 7-8 years follow-up [abstract]","author":"Kutlar","year":"2001"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB28|cit28","doi-asserted-by":"crossref","first-page":"Abst 3807","DOI":"10.1182\/blood.V108.11.3807.3807","article-title":"Time series analysis of the pain diary data obtained during the multicenter study for hydroxyurea (MSH) clinical trial [abstract]","author":"McCarthy","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD002202-BIB29|cit29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0197-2456(97)00014-7","article-title":"An extension of stochastic curtailment for incompletely reported events: The multicenter study of hydroxyurea in sickle cell anemia (MSH)","volume":"18","author":"McMahon","year":"1997","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202-BIB30|cit30","series-title":"Proceedings of the National Sickle Cell Didease Program 23rd Meeting; 1999 March","first-page":"210","article-title":"Cost-effectiveness of hydroxyurea in sickle cell anemia [abstract]","author":"Moore","year":"1999"},{"issue":"1","key":"10.1002\/14651858.CD002202-BIB31|cit31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<26::AID-AJH5>3.0.CO;2-F","article-title":"Cost-effectiveness of hydroxyurea in sickle cell anemia","volume":"64","author":"Moore","year":"2000","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD002202-BIB32|cit32","series-title":"Proceedings of the National Sickle Cell Disease Program 21st Meeting; 1996 March","first-page":"131","article-title":"The effect of hydroxyurea (HU) administration on circulating D-dimer levels in patients with sickle cell anemia (HbSS) [abstract]","author":"Orringer","year":"1996"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202-BIB33|cit33","first-page":"496a","article-title":"The effect of hydroxyurea (HU) administration on circulating d-dimer levels in patients with sickle cell anemia [abstract]","volume":"88","author":"Orringer","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB34|cit34","series-title":"3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20","first-page":"Abstract no: 25","article-title":"Effect of geography and climate on pain frequency in patients enrolled in the multicenter study of hydroxyurea in sickle cell anemia [abstract]","author":"Smith","year":"2009"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002202-BIB42|cit35","first-page":"8","article-title":"Determinants of fetal hemoglobin response to hydroxyurea","volume":"3","author":"Steinberg","year":"1997","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD002202-BIB43|cit36","series-title":"Proceedings of the National Sickle Cell Disease Program Annual Meeting; 1997 Sept","first-page":"68","article-title":"Mortality at 3-5 years: The multicenter study of hydroxyurea in sickle cell anemia (MSH) [abstract]","author":"Steinberg","year":"1997"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD002202-BIB35|cit37","first-page":"444a","article-title":"Mortality at 4-5 years: results from the multicenter study of hydroxyurea in sickle cell anemia (MSH) [abstract]","volume":"90","author":"Steinberg","year":"1997","journal-title":"Blood"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD002202-BIB36|cit38","first-page":"644a","article-title":"Risks and benefits of hydroxyurea (HU) in adult sickle cell anaemia. Effects at 6- to 7- years [abstract]","volume":"94","author":"Steinberg","year":"1999","journal-title":"Blood"},{"issue":"13","key":"10.1002\/14651858.CD002202-BIB37|cit39","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD002202-BIB38|cit40","first-page":"485a","article-title":"Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia [abstract]","volume":"96","author":"Steinberg","year":"2000","journal-title":"Blood"},{"issue":"10 Suppl 1 Pt 1","key":"10.1002\/14651858.CD002202-BIB39|cit41","first-page":"496a","article-title":"The multicenter study of hydroxyurea in sickle cell anemia (MSH): mortality at 5-6 years [abstract]","volume":"92","author":"Steinberg","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD002202-BIB40|cit42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.V89.3.1078","article-title":"Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea","volume":"89","author":"Steinberg","year":"1997","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002202-BIB41|cit43","first-page":"418a","article-title":"Fetal hemoglobin (Hb F) in sickle cell anemia (HbSS): Determinents of response to hydroxyurea (HU) [abstract]","volume":"86","author":"Steinberg","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB44|cit44","series-title":"Proceedings of the National Sickle Cell Disease Program 23rd Annual Meeting; 1999 March","first-page":"161","article-title":"Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia [abstract]","author":"Terrin","year":"1999"},{"issue":"12","key":"10.1002\/14651858.CD002202-BIB46|cit45","first-page":"1685","article-title":"Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease","volume":"91","author":"Montalembert","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB45|cit46","first-page":"Abst 3194","article-title":"A phase 1 pharmacokinetics (PK) study of hydroxyurea (HU) 1,000 mg coated breakable tablets and 500mg capsules in pediatric and adult patients with sickle cell disease [abstract]","volume":"106","author":"Montalembert","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB47|cit47","first-page":"298","article-title":"Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume [abstract]","volume":"Suppl 1","author":"Silva-Pinto","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD002202-BIB48|cit48","series-title":"10th Congress of the European Hematology Association; 2005 June 2-5; Stockholm International Fairs, Sweden","first-page":"Abst 0174","article-title":"Renal dysfunction and osteodystrophy in patients with sickle cell thalassaemia under long-term treatment with hydroxyurea [abstract]","author":"Voskaridou","year":"2005"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB49|cit49","doi-asserted-by":"crossref","first-page":"Abst 1213","DOI":"10.1182\/blood.V108.11.1213.1213","article-title":"Academic community standards for chronic transfusion therapy in children with sickle cell anemia and stroke [abstract]","volume":"108","author":"Ware","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB50|cit50","unstructured":"Jain D Low dose hydroxyurea in children severely affected with sickle cell disease: hospital based randomized controlled study [abstract] 4th Annual Sickle Cell Disease Research and Educational Symposium & Grant Writing Institute AND Annual Sickle Cell Disease Scientific Meeting ; 2010 Feb 14-19; Hollywood, Florida 2010 Abstract no: 076"},{"key":"10.1002\/14651858.CD002202-BIB51|cit51","doi-asserted-by":"crossref","unstructured":"Wang WC Snyder C Brugnara C Telen MJ Steinberg MH Wynn LW Effects of hydroxyurea (HU) and magnesium pidolate (Mg) in hemoglobin SC disease (HbSC): the \"CHAMPS\" trial [abstract] Blood 2009 Abstract no: 819","DOI":"10.1182\/blood.V114.22.819.819"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB52|cit52","doi-asserted-by":"crossref","first-page":"Abst 952","DOI":"10.1182\/blood.V106.11.952.952","article-title":"TCD in infants: A report from the BABY HUG trial [abstract]","volume":"106","author":"Adams","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB53|cit53","series-title":"28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio","first-page":"105","article-title":"TCD in infants: a report from the Baby Hug study [abstract]","author":"Adams","year":"2005"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB54|cit54","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V112.11.713.713","article-title":"Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial [abstract]","volume":"112","author":"Armstrong","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB55|cit55","series-title":"28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio","first-page":"137","article-title":"Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug) [abstract]","author":"Armstrong","year":"2005"},{"key":"10.1002\/14651858.CD002202-BIB56|cit56","unstructured":"McCarville MB\/\/Rees RC\/\/Rogers ZR\/\/Kalpatthi R\/\/Miller ST\/\/Wang WC\/\/the Baby Hug Investigators Adbominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial [abstract] 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009 Abstract no: 212"},{"key":"10.1002\/14651858.CD002202-BIB57|cit57","series-title":"29th Annual Meeting of the National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA","first-page":"Abst 141","article-title":"Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial [abstract]","author":"Miller","year":"2006"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V112.11.1413.1413","article-title":"Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial [abstract]","volume":"112","author":"Miller","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB59|cit59","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1182\/blood.V112.11.4791.4791","article-title":"Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial [abstract]","volume":"112","author":"Miller","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB60|cit60","doi-asserted-by":"crossref","unstructured":"Miller ST\/\/Wang WC\/\/Iyer R\/\/Rana S\/\/Lane P\/\/Ware RE\/\/Li D\/\/Rees RC Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG) Pediatric Blood & Cancer 2010 265 8","DOI":"10.1002\/pbc.22189"},{"key":"10.1002\/14651858.CD002202-BIB61|cit61","doi-asserted-by":"crossref","unstructured":"Pavlakis SG\/\/Rees RC\/\/Huang X\/\/Brown RC\/\/Casella JF\/\/Iyer RV\/\/Kalpatthi R\/\/Luden J\/\/Miller ST\/\/Rogers ZR\/\/Thornburg CD\/\/Wang WC\/\/Adams RJ Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial Pediatric Blood & Cancer 2010 256 9","DOI":"10.1002\/pbc.22282"},{"key":"10.1002\/14651858.CD002202-BIB62|cit62","series-title":"29th Annual Meeting of the National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA","first-page":"157","article-title":"Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial [abstract]","author":"Rogers","year":"2006"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V112.11.1416.1416","article-title":"Spleen function in infants with sickle cell anemia : baseline data from the BABY HUG trial [abstract]","volume":"112","author":"Rogers","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB64|cit64","series-title":"28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio","first-page":"106","article-title":"Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial [abstract]","author":"Rogers","year":"2005"},{"key":"10.1002\/14651858.CD002202-BIB65|cit65","series-title":"Blood","first-page":"Abst 3184","article-title":"Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial [abstract]","author":"Rogers","year":"2005"},{"key":"10.1002\/14651858.CD002202-BIB66|cit66","unstructured":"Rogers ZR\/\/Rees RC\/\/Files B\/\/Iyer RV\/\/Shulkin BL\/\/Shalaby-Rana E\/\/Miller JH\/\/Dertinger SD\/\/Lane PA\/\/Wang WC\/\/Ware RE\/\/The Baby Hug Investigators Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial [abstract] 3rd Annual Sickle Cell Disease Research and Educational Symposium AND Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20. 2009 Abstract no: 199"},{"key":"10.1002\/14651858.CD002202-BIB67|cit67","doi-asserted-by":"crossref","unstructured":"Thompson BW\/\/Miller ST\/\/Rogers ZR\/\/Rees RC\/\/Ware RE\/\/Waclawiw MA\/\/Iyer RV\/\/Casella JF\/\/Luchtman-Jones L\/\/Rana S\/\/Thornburg CD\/\/Kalpatthi RV\/\/Barredo JC\/\/Brown RC\/\/Sarnaik S\/\/Howard TH\/\/Luck L\/\/Wang WC The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design Pediatric Blood & Cancer 2010 250 5","DOI":"10.1002\/pbc.22269"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood.V112.11.1275.1275","article-title":"Study drug and visit adherence: data from the Baby HUG trial [abstract]","volume":"112","author":"Thornburg","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB69|cit69","doi-asserted-by":"crossref","unstructured":"Thornburg CD\/\/Rogers ZR\/\/Jeng MR\/\/Rana SR\/\/Iyer RV\/\/Faughnan L\/\/Hassen L\/\/Marshall J\/\/McDonald RP\/\/Wang WC\/\/Huang X\/\/Rees RC Adherence to study medication and visits: data from the BABY HUG trial Pediatric Blood & Cancer 2010 260 4","DOI":"10.1002\/pbc.22324"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood.V112.11.1436.1436","article-title":"Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial [abstract]","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB71|cit71","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood.V112.11.1414.1414","article-title":"Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial [abstract]","volume":"112","author":"Ware","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB72|cit72","doi-asserted-by":"crossref","unstructured":"Ware RE\/\/Rees RC\/\/Sarnaik SA\/\/Iyer RV\/\/Alvarez OA\/\/Casella JF\/\/Shulkin BL\/\/Shalaby-Rana E\/\/Strife CF\/\/Miller JH\/\/Lane PA\/\/Wang WC\/\/Miller ST Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial Journal of Pediatrics 2010 66 70","DOI":"10.1016\/j.jpeds.2009.06.060"},{"key":"10.1002\/14651858.CD002202-BIB73|cit73","series-title":"Proceedings of 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA","first-page":"245","article-title":"Recruitment in the Baby Hug pediatric hydroxyurea phase 3 clinical trial [abstract]","author":"Wynn","year":"2007"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.V112.11.1429.1429","article-title":"Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study [abstract]","volume":"112","author":"Wynn","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB75|cit75","series-title":"Proceedings of the National Sickle Cell Disease Program 21st Annual Meeting; 1996 March","first-page":"63","article-title":"Pattern of narcotic analgesic consumption among adult patients with sickle cell anemia [abstract]","author":"Ballas","year":"1996"},{"key":"10.1002\/14651858.CD002202-BIB76|cit76","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.1016\/0197-2456(96)84580-6","article-title":"Ascertainment of the primary end point in the Multicenter Study of Hydroxyrea in Sickle Cell Anemia (MSH). The MSH Investigators [abstract]","volume":"17","author":"Barton","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202-BIB77|cit77","first-page":"166","article-title":"Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group","volume-title":"Polycythemia vera and the myeloproliferation disorders","author":"Berk","year":"1995"},{"key":"10.1002\/14651858.CD002202-BIB78|cit78","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/pgmj.63.742.605","article-title":"Management of sickle cell disease","volume":"63","author":"Brozovic","year":"1987","journal-title":"Postgraduate Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD002202-BIB79|cit79","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0889-8588(18)30432-5","article-title":"Hydroxyurea as treatment for sickle cell anemia. [Review]","volume":"5","author":"Charache","year":"1991","journal-title":"Hematology - Oncology Clinics of North America"},{"issue":"10","key":"10.1002\/14651858.CD002202-BIB80|cit80","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","article-title":"Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]","volume":"79","author":"Charache","year":"1992","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB81|cit81","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002202-BIB82|cit82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0268-960X(97)90012-6","article-title":"Blood transfusion in sickle cell disease","volume":"11","author":"Davies","year":"1997","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD002202-BIB83|cit83","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/bmj.315.7109.656","article-title":"The management of patients with sickle cell disease","volume":"315","author":"Davies","year":"1997","journal-title":"British Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB84|cit84","first-page":"16b","article-title":"Hydroxyurea in children with sickle cell anaemia, should it be a life long treatment? [abstract]","volume":"96","author":"Alfy","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB85|cit85","first-page":"752a","article-title":"Long term experience of hydroxyurea treatment in sickle cell disease - Saudi experience [abstract]","volume":"96","author":"El-Hazmi","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB86|cit86","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues.","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002202-BIB87|cit87","first-page":"518a","article-title":"Acute leukemia (AL), hydroxyurea (HU), and polycythemia vera (PV): an analysis of risk from the Polycythemia Vera Study Group [abstract]","volume":"84","author":"Fruchtman","year":"1994","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB88|cit88","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/adc.75.3.199","article-title":"Pain, quality of life, and coping in sickle cell disease","volume":"75","author":"Fuggle","year":"1996","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD002202-BIB89|cit89","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jcp.44.6.459","article-title":"Mortality in sickle cell disease: the experience of a British centre","volume":"44","author":"Gray","year":"1991","journal-title":"Journal of Clinical Pathology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002202-BIB90|cit90","doi-asserted-by":"publisher","first-page":"92S","DOI":"10.1016\/0197-2456(96)84623-X","article-title":"Dose titration in the Multicentre Study of Hydroxyurea in Sickle Cell Anemia (MSH) [abstract]","volume":"17","author":"Handy","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002202-BIB91|cit91","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB92|cit92","first-page":"10a","article-title":"Long term use of hydroxyurea in adults with sickle cell disease: a large single centre experience [abstract]","volume":"96","author":"Kutlar","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD002202-BIB93|cit93","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.84.3.500","article-title":"Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease","volume":"84","author":"Leikin","year":"1989","journal-title":"Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD002202-BIB94|cit94","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1590\/S0100-879X1997000800004","article-title":"Minimal doses of hydroxyurea for sickle cell disease","volume":"30","author":"Lima","year":"1997","journal-title":"Brazilian Journal of Medical & Biological Research"},{"key":"10.1002\/14651858.CD002202-BIB95|cit95","series-title":"Proceedings of the National Sickle Cell Disease Program 23rd Meeting; 1999 March","first-page":"210","article-title":"Cost-effectiveness of hydroxyurea in sickle cell anemia [abstract]","author":"Moore","year":"1999"},{"issue":"1","key":"10.1002\/14651858.CD002202-BIB96|cit96","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<26::AID-AJH5>3.0.CO;2-F","article-title":"Cost-effectiveness of hydroxyurea in sickle cell anemia [abstract]","volume":"64","author":"Moore","year":"2000","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD002202-BIB97|cit97","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB98|cit98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-88-1-1","article-title":"Natural history of sickle cell anaemia in Saudi Arabs: a study of 270 subjects","volume":"88","author":"Perrine","year":"1978","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002202-BIB99|cit99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease: rates and risk factors [comment in: New England Journal of Medicine 1991; 325(24): 1747-8]","volume":"325","author":"Platt","year":"1991","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002202-BIB100|cit100","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease - life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002202-BIB101|cit101","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1542\/peds.71.6.927","article-title":"Is there an increased risk of Haemophilus influenzae septicemia in sickle cell anaemia?","volume":"71","author":"Powars","year":"1983","journal-title":"Pediatrics"},{"issue":"15","key":"10.1002\/14651858.CD002202-BIB102|cit102","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1056\/NEJM199004123221504","article-title":"Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea","volume":"322","author":"Rodgers","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002202-BIB103|cit103","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/bmj.1.6126.1515","article-title":"Early deaths in Jamaican children with sickle cell disease","volume":"1","author":"Rogers","year":"1978","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD002202-BIB104|cit104","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1046\/j.1365-2141.1997.3173132.x","article-title":"Cellular effects of hydroxyurea in Hb SC disease","volume":"98","author":"Steinberg","year":"1997","journal-title":"British Journal of Hematology"},{"key":"10.1002\/14651858.CD002202-BIB105|cit105","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199904013401307","article-title":"The Management of Sickle Cell Disease","volume":"340","author":"Steinberg","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002202-BIB106|cit106","first-page":"485a","article-title":"Hydroxyurea is associated with reduced mortality in adults with sickle cell anaemia","volume":"96","author":"Steinberg","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD002202-BIB107|cit107","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion [see comments]","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002202-BIB108|cit108","series-title":"Proceedings of the National Sickle Cell Disease Program 23rd Annual Meeting; 1999 March","first-page":"161","article-title":"Effect of hydroxyurea on quality of life: 2-year results from the multicenter study of hydroxyurea in sickle cell anemia [abstract]","author":"Terrin","year":"1999"},{"issue":"5","key":"10.1002\/14651858.CD002202-BIB109|cit109","first-page":"367","article-title":"Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease","volume":"36","author":"Triadou","year":"1994","journal-title":"Nouvelle Revue Francaise d Hematologie"},{"key":"10.1002\/14651858.CD002202-BIB110|cit110","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1056\/NEJM198512193132503","article-title":"Stimulation of F-cell production in patients with sickle cell anaemia treated with cytarabine or hydroxyurea","volume":"313","author":"Veith","year":"1985","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002202-BIB111|cit111","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V83.4.1124.1124","article-title":"A cautionary note regarding hydroxyurea in sickle cell disease","volume":"83","author":"Vichinsky","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD002202-BIB112|cit112","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2141.1995.tb08352.x","article-title":"Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell\/b thalassaemia","volume":"89","author":"Voskaridou","year":"1995","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD002202-BIB113|cit113","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood.V94.9.3022","article-title":"Hydroxyurea as an alternative to blood transfusions in the prevention of recurrent stroke in children with sickle cell disease","volume":"94","author":"Ware","year":"1999","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1002\/14651858.cd002202.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T13:15:06Z","timestamp":1704978906000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002202"}},"subtitle":[],"editor":[{"given":"Ashley P","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2001,4,23]]},"references-count":113,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002202","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD002202.pub2","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2001,4,23]]}}}